Clinical Trial Update: Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating early treatment with bosentan for sudden blindness due to giant cell arteritis; status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Arteritis

Drugs mentioned

• Bosentan (Bosentan)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nice | Conditions: Arteritis, Giant Cell, Blindness and Low Vision | Phase 3 | Status: UNKNOWN